Sunpharma Ltd — Q4 FY24
Sun Pharma reported Q4 FY24 consolidated revenue of INR 11,813 crore, up 10.1% YoY, driven by strong specialty sales (Ilumya up 21.7% to $580M globally) and India formulation gr...
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY24
R&D spend to touch lower end of 7% guidance for FY24
Management indicated that R&D spend for the full year is expected to reach the lower end of the 7% of sales guidance.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY24
Nidlegy filing with European authorities in H1 2024
Partner product Nidlegy is expected to be filed with European authorities during the first half of 2024.
Partial / close
Current-quarter commentary contains related evidence, but delivery is not conclusive enough for a clean met verdict.
heuristic_v1